Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis

Anushua Sinha, Orin Levine, Maria Deloria Knoll, Farzana Muhib, Tracy A. Lieu

Research output: Contribution to journalArticle

Abstract

Background: Routine vaccination of infants against Streptococcus pneumoniae (pneumococcus) needs substantial investment by governments and charitable organisations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate these data into an economic analysis of pneumococcal vaccination of infants in countries eligible for financial support from the Global Alliance for Vaccines & Immunization (GAVI). Methods: We constructed a decision analysis model to compare pneumococcal vaccination of infants aged 6, 10, and 14 weeks with no vaccination in the 72 countries that were eligible as of 2005. We used published and unpublished data to estimate child mortality, effectiveness of pneumococcal conjugate vaccine, and immunisation rates. Findings: Pneumococcal vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262 000 deaths per year (7%) in children aged 3-29 months in the 72 developing countries studied, thus averting 8·34 million disability-adjusted life years (DALYs) yearly. If every child could be reached, up to 407 000 deaths per year would be prevented. At a vaccine cost of International $5 per dose, vaccination would have a net cost of $838 million, a cost of $100 per DALY averted. Vaccination at this price was projected to be highly cost-effective in 68 of 72 countries when each country's per head gross domestic product per DALY averted was used as a benchmark. Interpretation: At a vaccine cost of between $1 and $5 per dose, purchase and accelerated uptake of pneumococcal vaccine in the world's poorest countries is projected to substantially reduce childhood mortality and to be highly cost-effective.

Original languageEnglish (US)
Pages (from-to)389-396
Number of pages8
JournalThe Lancet
Volume369
Issue number9559
DOIs
StatePublished - Feb 3 2007

Fingerprint

Child Mortality
Cost-Benefit Analysis
Vaccination
Economics
Costs and Cost Analysis
Quality-Adjusted Life Years
Pneumococcal Vaccines
Vaccines
Streptococcus pneumoniae
Immunization
Gross Domestic Product
Pertussis Vaccine
Financial Support
Benchmarking
Conjugate Vaccines
Tetanus Toxoid
Decision Support Techniques
Insurance Benefits
Health Care Costs
Developing Countries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality : an international economic analysis. / Sinha, Anushua; Levine, Orin; Knoll, Maria Deloria; Muhib, Farzana; Lieu, Tracy A.

In: The Lancet, Vol. 369, No. 9559, 03.02.2007, p. 389-396.

Research output: Contribution to journalArticle

Sinha, Anushua ; Levine, Orin ; Knoll, Maria Deloria ; Muhib, Farzana ; Lieu, Tracy A. / Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality : an international economic analysis. In: The Lancet. 2007 ; Vol. 369, No. 9559. pp. 389-396.
@article{6fa916e54fa14fbb8b3254ab3e80964a,
title = "Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis",
abstract = "Background: Routine vaccination of infants against Streptococcus pneumoniae (pneumococcus) needs substantial investment by governments and charitable organisations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate these data into an economic analysis of pneumococcal vaccination of infants in countries eligible for financial support from the Global Alliance for Vaccines & Immunization (GAVI). Methods: We constructed a decision analysis model to compare pneumococcal vaccination of infants aged 6, 10, and 14 weeks with no vaccination in the 72 countries that were eligible as of 2005. We used published and unpublished data to estimate child mortality, effectiveness of pneumococcal conjugate vaccine, and immunisation rates. Findings: Pneumococcal vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262 000 deaths per year (7{\%}) in children aged 3-29 months in the 72 developing countries studied, thus averting 8·34 million disability-adjusted life years (DALYs) yearly. If every child could be reached, up to 407 000 deaths per year would be prevented. At a vaccine cost of International $5 per dose, vaccination would have a net cost of $838 million, a cost of $100 per DALY averted. Vaccination at this price was projected to be highly cost-effective in 68 of 72 countries when each country's per head gross domestic product per DALY averted was used as a benchmark. Interpretation: At a vaccine cost of between $1 and $5 per dose, purchase and accelerated uptake of pneumococcal vaccine in the world's poorest countries is projected to substantially reduce childhood mortality and to be highly cost-effective.",
author = "Anushua Sinha and Orin Levine and Knoll, {Maria Deloria} and Farzana Muhib and Lieu, {Tracy A.}",
year = "2007",
month = "2",
day = "3",
doi = "10.1016/S0140-6736(07)60195-0",
language = "English (US)",
volume = "369",
pages = "389--396",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9559",

}

TY - JOUR

T1 - Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality

T2 - an international economic analysis

AU - Sinha, Anushua

AU - Levine, Orin

AU - Knoll, Maria Deloria

AU - Muhib, Farzana

AU - Lieu, Tracy A.

PY - 2007/2/3

Y1 - 2007/2/3

N2 - Background: Routine vaccination of infants against Streptococcus pneumoniae (pneumococcus) needs substantial investment by governments and charitable organisations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate these data into an economic analysis of pneumococcal vaccination of infants in countries eligible for financial support from the Global Alliance for Vaccines & Immunization (GAVI). Methods: We constructed a decision analysis model to compare pneumococcal vaccination of infants aged 6, 10, and 14 weeks with no vaccination in the 72 countries that were eligible as of 2005. We used published and unpublished data to estimate child mortality, effectiveness of pneumococcal conjugate vaccine, and immunisation rates. Findings: Pneumococcal vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262 000 deaths per year (7%) in children aged 3-29 months in the 72 developing countries studied, thus averting 8·34 million disability-adjusted life years (DALYs) yearly. If every child could be reached, up to 407 000 deaths per year would be prevented. At a vaccine cost of International $5 per dose, vaccination would have a net cost of $838 million, a cost of $100 per DALY averted. Vaccination at this price was projected to be highly cost-effective in 68 of 72 countries when each country's per head gross domestic product per DALY averted was used as a benchmark. Interpretation: At a vaccine cost of between $1 and $5 per dose, purchase and accelerated uptake of pneumococcal vaccine in the world's poorest countries is projected to substantially reduce childhood mortality and to be highly cost-effective.

AB - Background: Routine vaccination of infants against Streptococcus pneumoniae (pneumococcus) needs substantial investment by governments and charitable organisations. Policymakers need information about the projected health benefits, costs, and cost-effectiveness of vaccination when considering these investments. Our aim was to incorporate these data into an economic analysis of pneumococcal vaccination of infants in countries eligible for financial support from the Global Alliance for Vaccines & Immunization (GAVI). Methods: We constructed a decision analysis model to compare pneumococcal vaccination of infants aged 6, 10, and 14 weeks with no vaccination in the 72 countries that were eligible as of 2005. We used published and unpublished data to estimate child mortality, effectiveness of pneumococcal conjugate vaccine, and immunisation rates. Findings: Pneumococcal vaccination at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262 000 deaths per year (7%) in children aged 3-29 months in the 72 developing countries studied, thus averting 8·34 million disability-adjusted life years (DALYs) yearly. If every child could be reached, up to 407 000 deaths per year would be prevented. At a vaccine cost of International $5 per dose, vaccination would have a net cost of $838 million, a cost of $100 per DALY averted. Vaccination at this price was projected to be highly cost-effective in 68 of 72 countries when each country's per head gross domestic product per DALY averted was used as a benchmark. Interpretation: At a vaccine cost of between $1 and $5 per dose, purchase and accelerated uptake of pneumococcal vaccine in the world's poorest countries is projected to substantially reduce childhood mortality and to be highly cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=33846630415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846630415&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(07)60195-0

DO - 10.1016/S0140-6736(07)60195-0

M3 - Article

C2 - 17276779

AN - SCOPUS:33846630415

VL - 369

SP - 389

EP - 396

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9559

ER -